Autonomous bacterial nanoswimmers target cancer

ABSTRACT Injectable drug delivery systems that autonomously detect, propel towards, and ultimately treat the cancerous tissue, are the future of targeted medicine. Here, we developed a drug delivery system that swims autonomously towards cancer cells, where it releases a therapeutic cargo. This platform is based on viable bacteria, loaded with nanoparticles that contain the chemotherapeutic‐antibiotic drug doxorubicin. The bacteria ferry across media and invade the cancer cells, increasing their velocity in the presence of nutrients that are present within the tumor microenvironment. Inside the cancer cells, doxorubicin is released from the nanoparticles, destroying the bacterial swimmer (antibiotic activity) and executing the therapeutic activity against the cancer cells (chemotherapeutic activity). This mode of delivery, where both the carrier and the cancer cell are destroyed, supports implementing nanoswimmers in drug delivery (Fig. 1).

[1]  John Mao,et al.  Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Greiner,et al.  A Salmonella nanoparticle mimic overcomes multidrug resistance in tumours , 2016, Nature Communications.

[3]  V. Torchilin.  Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery , 2014, Nature Reviews Drug Discovery.

[4]  T Lammers,et al.  Tumour-targeted nanomedicines: principles and practice , 2008, British Journal of Cancer.

[5]  S. Martel,et al.  Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions , 2016, Nature nanotechnology.

[6]  Rachel W. Kasinskas,et al.  Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. , 2007, Cancer research.

[7]  Henry Hess,et al.  Molecular shuttles based on motor proteins , 2001 .

[8]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[9]  G. Otting,et al.  Molecular electroporation: a unifying concept for the description of membrane pore formation by antibacterial peptides, exemplified with NK‐lysin , 1999, FEBS letters.

[10]  Yuichi Hiratsuka,et al.  A microrotary motor powered by bacteria , 2006, Proceedings of the National Academy of Sciences.

[11]  Bert Vogelstein,et al.  Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  V. Vogel,et al.  Molecular shuttles based on motor proteins: active transport in synthetic environments. , 2001, Journal of biotechnology.

[13]  S. Howorka,et al.  Biomimetic Hybrid Nanocontainers with Selective Permeability , 2016, Angewandte Chemie.

[14]  J. Peyron,et al.  Modification of Salmonella Typhimurium Motility by the Probiotic Yeast Strain Saccharomyces boulardii , 2012, PloS one.

[15]  A. Chaussé,et al.  Multiplicity of Salmonella entry mechanisms, a new paradigm for Salmonella pathogenesis , 2012, MicrobiologyOpen.

[16]  Forrest M Kievit,et al.  Surface engineering of iron oxide nanoparticles for targeted cancer therapy. , 2011, Accounts of chemical research.

[17]  Bhushan J Toley,et al.  Motility is critical for effective distribution and accumulation of bacteria in tumor tissue. , 2012, Integrative biology : quantitative biosciences from nano to macro.

[18]  Shuming Nie,et al.  Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery , 2006, Molecular Cancer Therapeutics.

[19]  Toshio Fukuda,et al.  High efficiency motility of bacteria-driven liposome with raft domain binding method , 2012, Biomedical microdevices.

[20]  J. Pawelek,et al.  Tumor-targeted Salmonella. Highly selective delivery vectors. , 2000, Advances in experimental medicine and biology.

[21]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[22]  William S. Ryu,et al.  Real-Time Imaging of Fluorescent Flagellar Filaments , 2000, Journal of bacteriology.

[23]  J. Pawelek,et al.  Tumor-Targeted Salmonella , 2002 .

[24]  Pierre Nicolas,et al.  Multifunctional host defense peptides: intracellular‐targeting antimicrobial peptides , 2009, The FEBS journal.

[25]  J. Rao,et al.  Nanomechanical analysis of cells from cancer patients. , 2007, Nature nanotechnology.

[26]  N. Forbes.  Engineering the perfect (bacterial) cancer therapy , 2010, Nature Reviews Cancer.

[27]  I. Tannock,et al.  Acid pH in tumors and its potential for therapeutic exploitation. , 1989, Cancer research.

[28]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[29]  H. Berg,et al.  Movement of microorganisms in viscous environments , 1979, Nature.

[30]  J. Pawelek,et al.  Tumor-targeted Salmonella as a novel anticancer vector. , 1997, Cancer research.

[31]  Samuel I. Miller,et al.  Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo , 1999, Nature Biotechnology.

[32]  R. Langer,et al.  Photo-targeted nanoparticles. , 2010, Nano letters.

[33]  Meng Yang,et al.  Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Radmacher,et al.  pH Regulates Genes for Flagellar Motility, Catabolism, and Oxidative Stress in Escherichia coli K-12 , 2005, Journal of bacteriology.

[35]  L. Gerweck,et al.  Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. , 1996, Cancer research.

[36]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[37]  Joseph Kost,et al.  Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. , 2007, Langmuir : the ACS journal of surfaces and colloids.

[38]  Sabha Ganai,et al.  In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis , 2011, Cancer Gene Therapy.

[39]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[40]  R. Duncan,et al.  Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.

[41]  Meng Yang,et al.  Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. , 2006, Cancer research.

[42]  Joseph Kost,et al.  Ultrasound triggered release of cisplatin from liposomes in murine tumors. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[43]  H. Vogel,et al.  The expanding scope of antimicrobial peptide structures and their modes of action. , 2011, Trends in biotechnology.

[44]  Y. Huang,et al.  Oral delivery of tumor‐targeting Salmonella for cancer therapy in murine tumor models , 2007, Cancer science.

[45]  B. Williams,et al.  A self-propelled biohybrid swimmer at low Reynolds number , 2014, Nature Communications.

[46]  M. Belcourt,et al.  Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. , 2002, Human gene therapy.

[47]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[48]  J. Pawelek,et al.  Bacteria as tumour-targeting vectors. , 2003, The Lancet. Oncology.

[49]  Yechezkel Barenholz,et al.  In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[50]  Rachel W. Kasinskas,et al.  Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro , 2006, Biotechnology and bioengineering.

[51]  E. Fullerton,et al.  Cargo-towing fuel-free magnetic nanoswimmers for targeted drug delivery. , 2012, Small.

[52]  Z. Stachura,et al.  Elasticity of normal and cancerous human bladder cells studied by scanning force microscopy , 1999, European Biophysics Journal.

[53]  M. Ibrahim,et al.  Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question , 2014, Oncoscience.

[54]  John G. Gibbs,et al.  Nanopropellers and their actuation in complex viscoelastic media. , 2014, ACS nano.

[55]  Niv Papo,et al.  Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes? , 2003, Peptides.

[56]  J. A. Buchheim,et al.  Regulation of flagellar length in Chlamydomonas. , 2008, Seminars in cell & developmental biology.

[57]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[58]  H. Salman,et al.  Bacterial thermotaxis by speed modulation. , 2012, Biophysical journal.

[59]  M. Omar Din,et al.  Synchronized cycles of bacterial lysis for in vivo delivery , 2016, Nature.

[60]  Y. Huang,et al.  Oral delivery of tumor‐targeting Salmonella exhibits promising therapeutic efficacy and low toxicity , 2009, Cancer science.